line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,NATCOPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.178057,NATCOPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,25505000000.0,NATCOPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,,NATCOPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,NATCOPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,2352000000.0,NATCOPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,6898000000.0,NATCOPHARM.NS
EBITDA,2025-03-31 00:00:00,25505000000.0,NATCOPHARM.NS
EBIT,2025-03-31 00:00:00,23153000000.0,NATCOPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-239000000.0,NATCOPHARM.NS
Interest Expense,2025-03-31 00:00:00,239000000.0,NATCOPHARM.NS
Interest Income,2025-03-31 00:00:00,,NATCOPHARM.NS
Normalized Income,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Total Expenses,2025-03-31 00:00:00,24687000000.0,NATCOPHARM.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,NATCOPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,,NATCOPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,,NATCOPHARM.NS
Diluted EPS,2025-03-31 00:00:00,,NATCOPHARM.NS
Basic EPS,2025-03-31 00:00:00,,NATCOPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income,2025-03-31 00:00:00,18854000000.0,NATCOPHARM.NS
Minority Interests,2025-03-31 00:00:00,20000000.0,NATCOPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,18834000000.0,NATCOPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,18834000000.0,NATCOPHARM.NS
Tax Provision,2025-03-31 00:00:00,4080000000.0,NATCOPHARM.NS
Pretax Income,2025-03-31 00:00:00,22914000000.0,NATCOPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,3545000000.0,NATCOPHARM.NS
Special Income Charges,2025-03-31 00:00:00,,NATCOPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,NATCOPHARM.NS
Write Off,2025-03-31 00:00:00,,NATCOPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-239000000.0,NATCOPHARM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,NATCOPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,239000000.0,NATCOPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,NATCOPHARM.NS
Operating Income,2025-03-31 00:00:00,19608000000.0,NATCOPHARM.NS
Operating Expense,2025-03-31 00:00:00,17789000000.0,NATCOPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,9492000000.0,NATCOPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,2352000000.0,NATCOPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,2352000000.0,NATCOPHARM.NS
Research And Development,2025-03-31 00:00:00,,NATCOPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,NATCOPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,NATCOPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,NATCOPHARM.NS
Rent And Landing Fees,2025-03-31 00:00:00,,NATCOPHARM.NS
Gross Profit,2025-03-31 00:00:00,37397000000.0,NATCOPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,6898000000.0,NATCOPHARM.NS
Total Revenue,2025-03-31 00:00:00,44295000000.0,NATCOPHARM.NS
Operating Revenue,2025-03-31 00:00:00,44295000000.0,NATCOPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,NATCOPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.170421,NATCOPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,18795000000.0,NATCOPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,-75000000.0,NATCOPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,-75000000.0,NATCOPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,1868000000.0,NATCOPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,7166000000.0,NATCOPHARM.NS
EBITDA,2024-03-31 00:00:00,18795000000.0,NATCOPHARM.NS
EBIT,2024-03-31 00:00:00,16927000000.0,NATCOPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-192000000.0,NATCOPHARM.NS
Interest Expense,2024-03-31 00:00:00,192000000.0,NATCOPHARM.NS
Interest Income,2024-03-31 00:00:00,1010000000.0,NATCOPHARM.NS
Normalized Income,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Total Expenses,2024-03-31 00:00:00,24342000000.0,NATCOPHARM.NS
Rent Expense Supplemental,2024-03-31 00:00:00,59000000.0,NATCOPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,179506077.0,NATCOPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,179506077.0,NATCOPHARM.NS
Diluted EPS,2024-03-31 00:00:00,77.34,NATCOPHARM.NS
Basic EPS,2024-03-31 00:00:00,77.34,NATCOPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Minority Interests,2024-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,13883000000.0,NATCOPHARM.NS
Tax Provision,2024-03-31 00:00:00,2852000000.0,NATCOPHARM.NS
Pretax Income,2024-03-31 00:00:00,16735000000.0,NATCOPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,1281000000.0,NATCOPHARM.NS
Special Income Charges,2024-03-31 00:00:00,-68000000.0,NATCOPHARM.NS
Other Special Charges,2024-03-31 00:00:00,17000000.0,NATCOPHARM.NS
Write Off,2024-03-31 00:00:00,51000000.0,NATCOPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-192000000.0,NATCOPHARM.NS
Total Other Finance Cost,2024-03-31 00:00:00,72000000.0,NATCOPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,192000000.0,NATCOPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,1010000000.0,NATCOPHARM.NS
Operating Income,2024-03-31 00:00:00,15646000000.0,NATCOPHARM.NS
Operating Expense,2024-03-31 00:00:00,17176000000.0,NATCOPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,10058000000.0,NATCOPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,1868000000.0,NATCOPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,1868000000.0,NATCOPHARM.NS
Research And Development,2024-03-31 00:00:00,1417000000.0,NATCOPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,2683000000.0,NATCOPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,1530000000.0,NATCOPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,1153000000.0,NATCOPHARM.NS
Rent And Landing Fees,2024-03-31 00:00:00,59000000.0,NATCOPHARM.NS
Gross Profit,2024-03-31 00:00:00,32822000000.0,NATCOPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,7166000000.0,NATCOPHARM.NS
Total Revenue,2024-03-31 00:00:00,39988000000.0,NATCOPHARM.NS
Operating Revenue,2024-03-31 00:00:00,39988000000.0,NATCOPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-850446.687551,NATCOPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.170089,NATCOPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,10357000000.0,NATCOPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,-5000000.0,NATCOPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-5000000.0,NATCOPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,1638000000.0,NATCOPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,7455000000.0,NATCOPHARM.NS
EBITDA,2023-03-31 00:00:00,10352000000.0,NATCOPHARM.NS
EBIT,2023-03-31 00:00:00,8714000000.0,NATCOPHARM.NS
Net Interest Income,2023-03-31 00:00:00,367000000.0,NATCOPHARM.NS
Interest Expense,2023-03-31 00:00:00,95000000.0,NATCOPHARM.NS
Interest Income,2023-03-31 00:00:00,512000000.0,NATCOPHARM.NS
Normalized Income,2023-03-31 00:00:00,7157149553.312449,NATCOPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Total Expenses,2023-03-31 00:00:00,19068000000.0,NATCOPHARM.NS
Rent Expense Supplemental,2023-03-31 00:00:00,49000000.0,NATCOPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,182552365.0,NATCOPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,182552365.0,NATCOPHARM.NS
Diluted EPS,2023-03-31 00:00:00,39.18,NATCOPHARM.NS
Basic EPS,2023-03-31 00:00:00,39.18,NATCOPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Minority Interests,2023-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,7153000000.0,NATCOPHARM.NS
Tax Provision,2023-03-31 00:00:00,1466000000.0,NATCOPHARM.NS
Pretax Income,2023-03-31 00:00:00,8619000000.0,NATCOPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,141000000.0,NATCOPHARM.NS
Special Income Charges,2023-03-31 00:00:00,47000000.0,NATCOPHARM.NS
Other Special Charges,2023-03-31 00:00:00,-178000000.0,NATCOPHARM.NS
Write Off,2023-03-31 00:00:00,131000000.0,NATCOPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,367000000.0,NATCOPHARM.NS
Total Other Finance Cost,2023-03-31 00:00:00,50000000.0,NATCOPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,95000000.0,NATCOPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,512000000.0,NATCOPHARM.NS
Operating Income,2023-03-31 00:00:00,7901000000.0,NATCOPHARM.NS
Operating Expense,2023-03-31 00:00:00,11613000000.0,NATCOPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,2226000000.0,NATCOPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,1638000000.0,NATCOPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,1638000000.0,NATCOPHARM.NS
Research And Development,2023-03-31 00:00:00,902000000.0,NATCOPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,2030000000.0,NATCOPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,961000000.0,NATCOPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,1069000000.0,NATCOPHARM.NS
Rent And Landing Fees,2023-03-31 00:00:00,49000000.0,NATCOPHARM.NS
Gross Profit,2023-03-31 00:00:00,19514000000.0,NATCOPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,7455000000.0,NATCOPHARM.NS
Total Revenue,2023-03-31 00:00:00,26969000000.0,NATCOPHARM.NS
Operating Revenue,2023-03-31 00:00:00,26969000000.0,NATCOPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,38219584.569733,NATCOPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.159248,NATCOPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,3340000000.0,NATCOPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,240000000.0,NATCOPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,240000000.0,NATCOPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,1426000000.0,NATCOPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,6815000000.0,NATCOPHARM.NS
EBITDA,2022-03-31 00:00:00,3580000000.0,NATCOPHARM.NS
EBIT,2022-03-31 00:00:00,2154000000.0,NATCOPHARM.NS
Net Interest Income,2022-03-31 00:00:00,213000000.0,NATCOPHARM.NS
Interest Expense,2022-03-31 00:00:00,132000000.0,NATCOPHARM.NS
Interest Income,2022-03-31 00:00:00,390000000.0,NATCOPHARM.NS
Normalized Income,2022-03-31 00:00:00,1498219584.569733,NATCOPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Total Expenses,2022-03-31 00:00:00,17641000000.0,NATCOPHARM.NS
Rent Expense Supplemental,2022-03-31 00:00:00,32000000.0,NATCOPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,182409089.0,NATCOPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,182372169.0,NATCOPHARM.NS
Diluted EPS,2022-03-31 00:00:00,9.32,NATCOPHARM.NS
Basic EPS,2022-03-31 00:00:00,9.32,NATCOPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Minority Interests,2022-03-31 00:00:00,0.0,NATCOPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,1700000000.0,NATCOPHARM.NS
Tax Provision,2022-03-31 00:00:00,322000000.0,NATCOPHARM.NS
Pretax Income,2022-03-31 00:00:00,2022000000.0,NATCOPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,56000000.0,NATCOPHARM.NS
Special Income Charges,2022-03-31 00:00:00,228000000.0,NATCOPHARM.NS
Other Special Charges,2022-03-31 00:00:00,-427000000.0,NATCOPHARM.NS
Write Off,2022-03-31 00:00:00,199000000.0,NATCOPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,213000000.0,NATCOPHARM.NS
Total Other Finance Cost,2022-03-31 00:00:00,45000000.0,NATCOPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,132000000.0,NATCOPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,390000000.0,NATCOPHARM.NS
Operating Income,2022-03-31 00:00:00,1408000000.0,NATCOPHARM.NS
Operating Expense,2022-03-31 00:00:00,10826000000.0,NATCOPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,2292000000.0,NATCOPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,1426000000.0,NATCOPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,1426000000.0,NATCOPHARM.NS
Research And Development,2022-03-31 00:00:00,1769000000.0,NATCOPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,1255000000.0,NATCOPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,437000000.0,NATCOPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,818000000.0,NATCOPHARM.NS
Rent And Landing Fees,2022-03-31 00:00:00,32000000.0,NATCOPHARM.NS
Gross Profit,2022-03-31 00:00:00,12234000000.0,NATCOPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,6815000000.0,NATCOPHARM.NS
Total Revenue,2022-03-31 00:00:00,19049000000.0,NATCOPHARM.NS
Operating Revenue,2022-03-31 00:00:00,19049000000.0,NATCOPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,NATCOPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,NATCOPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,NATCOPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,203000000.0,NATCOPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,203000000.0,NATCOPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,NATCOPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,NATCOPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,NATCOPHARM.NS
EBITDA,2021-03-31 00:00:00,,NATCOPHARM.NS
EBIT,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,NATCOPHARM.NS
Interest Expense,2021-03-31 00:00:00,,NATCOPHARM.NS
Interest Income,2021-03-31 00:00:00,566000000.0,NATCOPHARM.NS
Normalized Income,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,NATCOPHARM.NS
Total Expenses,2021-03-31 00:00:00,,NATCOPHARM.NS
Rent Expense Supplemental,2021-03-31 00:00:00,30000000.0,NATCOPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,182494899.0,NATCOPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,182158796.0,NATCOPHARM.NS
Diluted EPS,2021-03-31 00:00:00,24.16,NATCOPHARM.NS
Basic EPS,2021-03-31 00:00:00,24.2,NATCOPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,NATCOPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Income,2021-03-31 00:00:00,,NATCOPHARM.NS
Minority Interests,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,NATCOPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,NATCOPHARM.NS
Tax Provision,2021-03-31 00:00:00,,NATCOPHARM.NS
Pretax Income,2021-03-31 00:00:00,,NATCOPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,NATCOPHARM.NS
Special Income Charges,2021-03-31 00:00:00,203000000.0,NATCOPHARM.NS
Other Special Charges,2021-03-31 00:00:00,-320000000.0,NATCOPHARM.NS
Write Off,2021-03-31 00:00:00,117000000.0,NATCOPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,NATCOPHARM.NS
Total Other Finance Cost,2021-03-31 00:00:00,45000000.0,NATCOPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,NATCOPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,566000000.0,NATCOPHARM.NS
Operating Income,2021-03-31 00:00:00,,NATCOPHARM.NS
Operating Expense,2021-03-31 00:00:00,,NATCOPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,,NATCOPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,NATCOPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,NATCOPHARM.NS
Research And Development,2021-03-31 00:00:00,1473000000.0,NATCOPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,906000000.0,NATCOPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,341000000.0,NATCOPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,565000000.0,NATCOPHARM.NS
Rent And Landing Fees,2021-03-31 00:00:00,30000000.0,NATCOPHARM.NS
Gross Profit,2021-03-31 00:00:00,,NATCOPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,NATCOPHARM.NS
Total Revenue,2021-03-31 00:00:00,,NATCOPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,NATCOPHARM.NS
